Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN international activities

This article was originally published in The Tan Sheet

Executive Summary

Strengthening CFSAN's participation and leadership in the Codex Alimentarius Commission, including the Nutrition & Foods for Special Dietary Uses committee, is one of many priorities announced in the center's "Draft Affirmative Agenda for International Activities" for 2000-2002. A Sept. 17 Federal Register notice provides a 45-day written comment period on the agenda, which also includes inspecting high-risk foreign food production facilities for compliance with FDA regulations on infant formula and investigating alternatives for animal testing of foods and cosmetics. The draft agenda is available on CFSAN's Web site. Developing a clearer international agenda was one of the center's "A-List" priorities for 1999 (1"The Tan Sheet" Feb. 1, p. 9)

You may also be interested in...



CFSAN Strategic Plan Focuses On Ephedra, Nutrient Content/Health Claims

FDA's Center for Food Safety & Applied Nutrition strategic plan, entitled "1999 CFSAN Program Priorities," addresses issues surrounding the dietary supplement ephedra as well as publishing a proposed rule covering nutrient content/health claims based on authoritative statements. The plan was discussed at a press briefing Jan. 26.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel